Proteomic analysis of sera from individuals with diffuse cutaneous systemic sclerosis reveals a multianalyte signature associated with clinical improvement during imatinib mesylate treatment Academic Article uri icon

Overview

MeSH Major

  • Autoantibodies
  • Autoantigens
  • RNA Processing, Post-Transcriptional
  • Scleroderma, Systemic

abstract

  • Identification of patients with SSc with the greatest probability of benefit from treatment with imatinib has the potential to guide individualized treatment. Validation of the signature will require testing in randomized, placebo-controlled studies. Clinicaltrials.gov NCT00555581 and NCT01166139.

publication date

  • May 2017

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.3899/jrheum.160833

PubMed ID

  • 28298564

Additional Document Info

start page

  • 631

end page

  • 638

volume

  • 44

number

  • 5